Rapporteur- Farbod Dehghani: Iran’s health system thanks to medical advances fortunately is in a position that in addition to competing with the best countries in the world, also a large number of foreign patients come here to continue treatment, facing high costs problem.
In many parts of the country, especially deprived areas, many people are unable to pay their medical expenses. This leads to serious problems for them and a simple illness become hard ill causes of late begin.
In the case of most less-complex and curable conditions, pharmaceutical companies have been successful in developing multiple effective drugs. As there are many substitutes, competition among the pharmaceutical companies keeps prices reasonable. For example, there are many antibiotics to treat pneumonia, with a defined treatment duration. If a patient initiates therapy with one antibiotic and is cured, the patient will not need to use other antibiotics. Therefore, there is genuine competition among pharmaceutical companies to provide the most effective product with the least adverse effects at the best value. This is seldom the case in cancer therapy.
Although the same situation may occur in other chronic incurable illnesses, the magnitude of the problem is amplified in malignancies because the impact and seriousness of a cancer diagnosis results in greater willingness on the part of patients and physicians to take on the high costs of treatment. This is evidenced by the elasticities (percentage change in use associated with a 1% increase in effective coinsurance rates) of specialty drug use by patients among 4 conditions.(1)
Although health the development program is one of the valuable achievements of the government, and largely a problem of governmental hospitals expenses is solved, but the cost of treatment in the private sector is still high and due to the limited capacity of public hospitals, it requires more attention.